Abstract
Background:
Multimorbidity is defined as co-existence of two-or-more chronic health conditions in an individual. The prevalence of multimorbidity has been increasing over the years, and it has emerged as a growing public health concern globally. In Aotearoa New Zealand (NZ), about one in four of the adult population has multimorbidity. Multimorbidity is associated with reduced quality of life, increased morbidity and mortality, and severe financial burden on patients, their caregivers and the health system.
Despite the growing interest in multimorbidity research and in the best approaches for health services, the evidence remains limited to reach firm conclusions on the healthcare utilisation and health related quality of life (HRQoL) outcomes for interventions used to improve health outcomes of people with multimorbidity as compared to usual care. Additionally, cost information related to the use of healthcare resources associated with the interventions used to manage multimorbidity is generally not widely reported. High costs associated with managing multimorbidity highlight the importance of having value for money assessments on the interventions used to manage multimorbidity. In addition to the clinical effectiveness and cost-effectiveness (value for money) components for the interventions used to manage multimorbidity, affordability has become another key decision-making component in the health technology assessment process.
Thus, this study was conducted with three objectives: i) to perform a systematic review to report and summarise the cost and effectiveness of interventions used to improve the health outcomes of people with multimorbidity, ii) to conduct an economic evaluation on interventions used to improve the health outcomes of people with multimorbidity in from the perspective of the NZ health system, iii) to estimate the budget impact of interventions used to improve the health outcomes of people with multimorbidity from the payer’s perspective of the NZ health system.
Methods:
We performed an updated systematic review based on the previous work done by Smith et al. 2021 to address the existing evidence gap by providing an up-to-date synthesis of both the clinical and economic effectiveness of interventions used to improve health outcomes for people with multimorbidity in primary care and community settings. We searched the MEDLINE, EMBASE and CINAHL databases, the Cochrane Library, two trials registers, and grey literature for articles published up to 30 September 2024. Studies of adults with multimorbidity receiving care in primary or community care settings were included. Two reviewers independently screened studies for eligibility, extracted data, and assessed risk of bias and certainty of evidence with the GRADE approach. Interventions were categorised as medicines management (MM), support for self-management (SSM), or care coordination plus support for self-management (CC + SSM). Meta-analysis for primary outcomes (HRQoL, healthcare utilisation, and healthcare costs) was conducted (Chapter 2).
Our systematic review synthesised findings from studies conducted in international contexts. To assess the applicability of these findings to the local context, we consulted experts to evaluate the feasibility of implementing these identified interventions. In addition, experts were consulted on the resources required for the implementation of these interventions in the NZ context. This information is used to inform the input parameters for the CEA and BIA. Consultations with experts were performed either in person or by virtual meeting using interview guides. All interviews were shorthand documented and transcribed manually by typing out into text format. Data collected from the experts were summarised and compiled (Chapter 3).
To evaluate the cost-effectiveness of the interventions used to manage multimorbidity from the perspective of NZ health system, a discrete event simulation model was developed to simulate adult individuals with multimorbidity in NZ. Individuals receiving each of the three interventions (MM, SSM, and CC + SSM) alongside usual care were modelled for health events (hospitalisation, emergency department visits, general practitioner visits, and outpatient visits) until death or age 100. Data on event rates, HRQoL, and costs were extracted from the Statistics NZ’s Integrated Data Infrastructure or calculated using reference prices. Intervention effectiveness data from our systematic review were used to model event rate changes. All costs were expressed in 2025 NZ dollars (NZD), and both the costs and quality-adjusted life-years were discounted at 3.5%. Probabilistic sensitivity analysis was applied to incorporate the uncertainty in treatment effects. Univariate sensitivity analyses were performed to assess the uncertainties associated with the discount rates and interventions costs. The simulation was programmed in R using the descem package (Chapter 4).
A budget impact model was developed to estimate the budget impact of additional interventions (MM, SSM, and CC + SSM) use in the management of people with multimorbidity. We developed the budget impact model based on the guidance of the ISPOR 6-step framework. The analytical framework for budget impact analysis (BIA) was based on NZ epidemiologic data and the effects of these interventions from the findings of our systematic review. The total costs associated with each of the three interventions (new scenarios) were analysed separately, and each compared to the current usual care practice (current scenario). The net budget impact is the difference in the total budget between the two scenarios. The analysis was conducted from the NZ health system payer’s perspective (Chapter 5).
Results:
From 10,272 titles screened in the systematic review, 33 eligible studies (this review: 18, previous review: 15; MM: 6, SSM: 9, CC + SSM: 18) were identified, of which 26 studies with 9,449 participants were included in meta-analysis. Overall, there was little significant evidence of benefit of the interventions compared with usual care for most outcomes. Compared to usual care, MM was associated with slightly better health utility score (0.024, 95%CI -0.007 to 0.056, low certainty). SSM was associated with better health utility (0.018, 95%CI -0.001 to 0.038, low certainty), lower hospitalisation risk (OR 0.55, 95%CI 0.32 to 0.97, low certainty) and medication costs (-110 USD/year, 95%CI -151 to -68, moderate certainty), but slightly more emergency department visits (0.15/year, 95%CI 0.02 to 0.27, moderate certainty). CC + SSM was associated with slightly better SF-12 PCS scores (0.779, 95%CI 0.200 to 1.358, moderate certainty), and lower hospitalisation risk (OR 0.56, 95%CI 0.39 to 0.81, moderate certainty), but more outpatient (0.38/year, 95%CI 0.17 to 0.59, moderate certainty) and general practitioner (GP) visits (3.69/year, 95%CI 0.41 to 6.96, very low certainty).
To deliver MM interventions, experts indicated that an annual 15-minute consultation with a GP is required, along with a 45-minute session every six months with community pharmacists for medication reconciliation and counselling. For SSM interventions, expert consensus suggested three 30-minute sessions per year with health coaches or health improvement practitioners. For CC + SSM interventions, expert feedback indicated the need for a 30-minute multidisciplinary team (comprising two specialist doctors, one GP, one nurse, and one allied health professional) consultation every four months, alongside the SSM interventions.
In the primary analysis of our economic evaluation, the incremental cost-effectiveness ratio (ICER) for MM interventions was estimated at NZD 18,942 per quality-adjusted life-years (QALY), as compared to usual care alone. SSM interventions were found to have an ICER of NZD 22,728 per QALY. The ICERs of both these interventions were found below one GDP per capital threshold of NZD 82,643 per QALY, indicating that implementing the MM and the SSM interventions to patients with multimorbidity were cost-effective from the health system perspective. In contrast, the incremental cost of the CC + SSM interventions was NZD 22,488 and the incremental QALY was –0.09, which was found to be dominated by usual care and was deemed as not cost-effective. The results of all the other secondary analyses and subgroup analyses were consistent with the results of the primary analysis in which both the MM and the SSM interventions were cost-effective but the CC + SSM interventions were dominated by usual care and were not cost-effective. Sensitivity analyses using different discount rates and variation in intervention costs revealed that the findings were robust and aligned with the primary analysis. The cost-effectiveness findings were stable across alternative cost-effectiveness thresholds at 0.5 and two GDP per capita.
In the BIA, implementation of the MM interventions would lead to an increased in total budget expenditure of around NZD 260 million over 5 years, for a total of 490,498 multimorbid patients. Compared to usual care, an incremental 5-year total net budget impact of about NZD 631 million (total 980,996 patients) and NZD 383 million (total 367,874 patients) were required for the implementation of the SSM and CC + SSM interventions. In the secondary analyses, smaller net budget impacts were found when smaller size of population was identified from the Publicly Funded Hospital Discharges dataset, and complex multimorbid populations identified from both the datasets. Sensitivity analyses revealed that the results were robust to reasonable changes in the annual cost and adoption rates of the MM, SSM, and CC + SSM interventions, but sensitive to uncertainty in treatment effects, especially on hospitalisation and outpatient visits.
Conclusions:
The findings from the meta-analysis revealed suggestive but inconclusive evidence of improved outcomes and reduced healthcare utilisation, especially hospitalisation, for these interventions, but a particular paucity of reporting of healthcare costs. Both the MM and SSM interventions were found to be cost-effective compared to usual care, demonstrate potential for broader adoption in healthcare systems. In contrast, the CC + SSM interventions were dominated by the usual care and may not be recommended for implementation. Implementing all the three types of interventions showed incremental net budget impact, indicating an additional budget is required from the health system payer’s perspective. This study provides a comprehensive summary on the clinical effectiveness evidence, economic evaluation and BIA presented with real-world data and clinical expert perspectives for the interventions used to improve the health outcomes of individuals with multimorbidity. It is hoped that the work done in this thesis and recommendations could support the translational value and usefulness of bringing the research into practice to healthcare providers, policymakers and researchers in this area. However, future research is required especially to address gaps on the limited evidence found on the treatment effects of the interventions.